Author Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial

Neurology. 2022 Aug 9;99(6):260-261. doi: 10.1212/WNL.0000000000201005.
No abstract available

Publication types

  • Comment

MeSH terms

  • Genetic Therapy / adverse effects
  • Humans
  • Levodopa
  • Parkinson Disease* / genetics
  • Parkinson Disease* / therapy

Substances

  • Levodopa